GXAI

Gaxos.ai
GXAI

$2.35

1.26%

Market Cap: $2.81M

About: Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Employees: 3

Information Technology Prepackaged Software

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

8.68% less ownership

Funds ownership: 18.45% [Q1] → 9.77% (-8.68%) [Q2]

63% less funds holding

Funds holding: 8 [Q1] → 3 (-5) [Q2]

73% less capital invested

Capital invested by funds: $1.11M [Q1] → $296K (-$813K) [Q2]

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GXAI.

See Analyst Rankings

Financial journalist opinion

Gaxos.AI Successfully Completes Development of AI Solution for Game Developers and Publishers

Roseland, NJ, June 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that its gaming division, has successfully completed development of its AI solution for game developers and publishers.

Gaxos.AI Successfully Completes Development of AI Solution for Game Developers and Publishers

Gaxos Health Expands Medical Advisory Board

Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.

Gaxos Health Expands Medical Advisory Board

Gaxos.ai Regains Compliance with Nasdaq Listing Requirements

Roseland, NJ, March 26, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on March 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

Gaxos.ai Regains Compliance with Nasdaq Listing Requirements

Gaxos.ai Inc. Announces Closing of $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules

Roseland, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it has closed its previously announced private placement for the purchase and sale of 628,367 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 628,367 shares of common stock and short-term series B warrants to purchase up to 628,367 shares of common stock at a purchase price of $5.57 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $5.50 per share and are exercisable immediately upon issuance. The series A warrants expire five and one-half years from the date of issuance and short-term series B warrants expire twenty-four months from the date of issuance.

Gaxos.ai Inc. Announces Closing of $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules

Gaxos.ai Inc. Announces $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules

Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 628,367 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 628,367 shares of common stock and short-term series B warrants to purchase up to 628,367 shares of common stock at a purchase price of $5.57 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $5.50 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire twenty-four months from the date of issuance. The private placement is expected to close on or about March 15, 2024, subject to the satisfaction of customary closing conditions.

Gaxos.ai Inc. Announces $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules

Why Is Gaxos.ai (GXAI) Stock Up 134% Today?

Gaxos.ai (NASDAQ: GXAI ) stock is heading higher on Wednesday after the artificial intelligence ( AI ) app company obtained rights to new AI-enabled technology. According to a press release from Gaxos.ai, the company has secured the rights to this AI tech from biohacking app Ultiself.

Why Is Gaxos.ai (GXAI) Stock Up 134% Today?

Gaxos Acquires Rights to AI-enabled Technology from Top Biohacking App

Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, “Ultiself,” in order to facilitate the development of its tech for Gaxos Health.

Gaxos Acquires Rights to AI-enabled Technology from Top Biohacking App

See News Rankings